The short version of clinical evidence fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-25 and is reviewed periodically as new material appears.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Dry powder storage | -20 °C or below | Desiccated and protected from light |
| Solution storage | 2-8 °C, short term | Aliquot to avoid freeze-thaw cycling |
| Reconstitution solvent | Water or buffered saline | Near-neutral pH is generally preferred |
| Identity confirmation | Mass spectrometry | Matches expected monoisotopic mass |
| Purity assessment | Reverse-phase HPLC | Reported as main-peak area percentage |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
== Assembly == Direct interaction of two nascent proteins emerging from nearby ribosomes appears to be a general mechanism for oligomer formation. Hundreds of protein oligomers were identified that assemble in human cells by such an interaction. The most prevalent form of interaction was between the N-terminal regions of the interacting proteins. Dimer formation appears to be able to occur independently of dedicated assembly machines.
whereas if the integral is greater than one the disease will not die out and there may be such resonances. For example, considering the periodically varying contact rate as the 'input' of the system one has that the output is a periodic function whose period is a multiple of the period of the input. This allowed to give a contribution to explain the poly-annual (typically biennial) epidemic outbreaks of some infectious diseases as interplay between the period of the contact rate oscillations and the pseudo-period of the damped oscillations near the endemic equilibrium. Remarkably, in some cases, the behavior may also be quasi-periodic or even chaotic.
The Unitized Group Ration – Express (UGR-E or UGR-Express), nicknamed the "kitchen in a carton", consists of meals in self-heating steam table trays based on the UGR-H&S meal offerings. The UGR-E is designed to provide hot meals where feeding a group with hot food would otherwise be unfeasible. Unlike other UGRs, it uses a flameless ration heater and does not require a separate field kitchen. The UGR-E begins heating with the pull of a tab, and can fully heat a meal within 30 to 45 minutes. The UGR-E has 4 breakfast menus, 8 lunch/dinner menus, and 1 holiday menu. Each meal provides an average of 1,300 kcal. Each UGR-E module contains 18 meals, with each pallet holding 400 meals. UGR-E modules have a minimum shelf life of 18 months at 80 °F (26.6 °C).
However, not all were convinced by Fermi's analysis of his results, though he would win the 1938 Nobel Prize in Physics for his "demonstrations of the existence of new radioactive elements produced by neutron irradiation, and for his related discovery of nuclear reactions brought about by slow neutrons". The German chemist Ida Noddack notably suggested in 1934 that instead of creating a new, heavier element 93, that "it is conceivable that the nucleus breaks up into several large fragments." However, the quoted objection comes some distance down, and was but one of several gaps she noted in Fermi's claim. Although Noddack was a renowned analytical chemist, she lacked the background in physics to appreciate the enormity of what she was proposing.
==== Dopamine receptor agonists ==== Apomorphine (Apofin; CHF-1526) – non-selective dopamine receptor agonist and other actions [330] Apomorphine subcutaneous (APO-go; Apokinon; Apokyn; Apomine; Britaject; KW-6500; Li Ke Ji; Movapo; Onapgotm; SPN-830) – non-selective dopamine receptor agonist and other actions [331] Bromocriptine (Parlodel) – dopamine D2-like receptor agonist and other actions Cabergoline (Dostinex) – dopamine D2-like receptor agonist and other actions Dihydroergocryptine (DHEC; Almirid; Cripar) – dopamine D2-like receptor agonist and other actions Lisuride (Dopergin) – dopamine D2-like receptor agonist and other actions Pergolide (Permax) – dopamine D2-like receptor agonist and other actions Piribedil (Trivastal, Pronoran) – dopamine D2-like receptor agonist and other actions Pramipexole (BI-Sifrol; Daquiran; Mirapex; Mirapexin; Pexola; Sifrol; SND-919; SND-919Y) – dopamine D2, D3, and D4 receptor agonist [332] Ropinirole (Adartrel; Repreve; Requip) – dopamine D2, D3, and D4 receptor agonist [333] Ropinirole (Requip CR; Requip LP; Requip XL; Requip XR; SKF-101468A) – dopamine D2, D3, and D4 receptor agonist [334] Ropinirole transdermal (Haruropi Tape; HP-3000) – non-selective dopamine receptor agonist and other actions [335] Rotigotine transdermal (Leganto; N-0437; N-0923; Neupro; Neupro Patch; Nubrenza; SPM-962) – non-selective dopamine receptor agonist and other actions [336] Talipexole (BHT-920; Domin) – dopamine D2 receptor agonist and α2-adrenergic receptor agonist [337]
Sources: en.wikipedia.org
Parathyroid hormone-related protein (PTHrP) is a proteinaceous hormone and a member of the parathyroid hormone family secreted by mesenchymal stem cells. It is occasionally secreted by cancer cells (for example, breast cancer, certain types of lung cancer including squamous-cell lung carcinoma). However, it also has normal functions in bone, teeth, vascular tissues and other tissues.
=== Reactions of substituents === In addition to the reactions of pyridinenitrogen, substituted pyridines can react at the CH sites and at the substituents. The survey below emphasizes the latter, being organized in parallel to the principal substituents.
Subglandular implant-pocket: The plastic surgeon emplaces the breast implant to the retromammary space — between the breast tissue and the pectoralis major muscle — which is the orientation that most approximates the normal plane of the breast. Although this surgical approach to emplacing a prosthetic breast yields the most aesthetic results, in women with a small volume of soft-tissue in the breast, the subglandular emplacement of the implant is likelier to ripple and wrinkle the skin-envelope of the breast. Subfascial implant-pocket: The surgeon emplaces the prosthetic breast beneath the fascia (the membrane that covers and encloses the pectoralis major muscle) to augment the size and volume of the breast hemisphere, for subsequent contouring and anatomic symmetry. Subpectoral implant-pocket: In this dual-plane surgical approach, the surgeon emplaces the breast implant beneath the pectoralis major muscle (after partially cutting the inferior attachments of that muscle) with or without the partial cutting of the subglandular plane of the breast. Resultantly, the upper-half of the breast-implant is partially beneath the pectoralis major muscle, while the lower-half of the implant is in the subglandular plane of the breast being augmented. This emplacement technique achieves maximal coverage of the upper-half of the breast implant, whilst allowing the maximal expansion of the lower-half of the implant to achieve maximal breast-volume; however, there exists the risk of animation deformity, the breast-implant moving in place beneath the subpectoral plane.
Overall, without considering race, approximately 1.5% of infants born in the United States are carriers of at least one copy of the mutant (disease-causing) gene. In June 2026 it was reported that Daniel Cressy, an African American from Louisiana was cured from the disease after going through curative gene therapy.
(1933), first African-American basketball player to be selected as All-American Alfred Skrobisch (1933), Olympic fencer Cliff Montgomery (1934), led the Columbia Lions football team to victory in the Rose Bowl John O'Brien (1938), basketball player for the Akron Wingfoots Ben Johnson (1938), sprinter who rivaled Jesse Owens Sid Luckman (1939), NFL Hall of Fame Chicago Bears quarterback Ken Germann (1943), football coach, athletic director of Columbia University, and former Southern Conference commissioner Paul Governali (1943), football player for the Boston Yanks and New York Giants Walt Budko (1948), basketball player for Baltimore Bullets and Philadelphia Warriors Bruce Gehrke (1948), football player for New York Giants Bill Swiacki (1948), player for New York Giants, member of the College Football Hall of Fame Lou Kusserow (1949), football player for Hamilton Tiger-Cats and New York Yanks John Azary (1951), basketball player, recipient of the Haggerty Award Jack Molinas (1953), NBA player for the Fort Wayne Pistons Jack Rohan (1953), head coach of the Columbia Lions men's basketball team 1961–1974, and 1990–1995 George Shaw (1953), Olympic triple jumper Richard Ballantine* (1967), cyclist and cycling advocate; son of Ian Ballantine '38 of Ballantine Books James Margolis (1958), Olympic fencer James Melcher (1961), Olympian fencer, president of Fencers Club and hedge fund manager Robert Contiguglia (1963), soccer player, former president of the United States Soccer Federation Peter Salzberg (1964), head coach of Vermont Catamounts men's basketball 1972–1981 Archie Roberts (1965), former football player for the Miami Dolphins and cardiac surgeon Jim McMillian (1968), NBA player for the Los Angeles Lakers, Buffalo Braves, New York Knicks and Portland Trail Blazers Dave Newmark (1968), NBA player for the Chicago Bulls; also played for Israeli team Hapoel Tel Aviv B.C. Marty Domres (1969), football player for San Diego Chargers and Baltimore Colts Heyward Dotson (1970), basketball player George Starke (1971), offensive lineman for the Washington Redskins Henry Bunis (1975), two-time All-American tennis player, runner-up in 1977 Chilean Open Rick Fagel (1975), professional tennis player Vitas Gerulaitis* (1975), champion tennis player Thomas Losonczy (1975), Olympic fencer, winner of the Congressional Gold Medal Alton Byrd (1979), basketball player Eric Fromm (1980), tennis player John Witkowski (1983), football player for Detroit Lions and Houston Oilers Gene Larkin (1984), member of the Minnesota Twins 1987 and 1991 World Series championship teams Amr Aly (1985), soccer player who won the Hermann Trophy as the top college player of the year 1984; member of the 1984 U.S. Olympic Soccer Team and indoor soccer team Los Angeles Lazers Stephen Trevor (1986), Olympic fencer Kyra Tirana Barry (1987), team leader for U.S. women's national wrestling team Caitlin Bilodeaux (1987), Olympic fencer Howard Endelman (1987), tennis player Phil Williamson (1987), tennis player for Antigua and Barbuda Bob Cottingham (1988), Olympic fencer Jon Normile (1989), Olympic fencer Frank Seminara (1989), Major League Baseball pitcher for the San Diego Padres and the New York Mets Tom Auth (1990), Olympic rower Christine Vardaros (1991), professional cyclist Ann Marsh (1994), Olympic fencer Ríkharður Daðason (1996), Icelandic soccer player Marcellus Wiley (1997), football player for the Buffalo Bills, San Diego Chargers and Dallas Cowboys Dan Kellner (1998), fencer Pellegrino Matarazzo (1999), head coach of VfB Stuttgart Matt Napoleon (1999), Olympic soccer goalkeeper Cristina Teuscher (2000), Olympic gold medalist swimmer Jedediah Dupree (2001), NCAA Champion fencer Veljko Urošević (2003), Serbian Olympic rower Fernando Perez (2004), outfielder for the Tampa Bay Rays Jeremiah Boswell (2005), professional basketball player for BC Sliven, KK Strumica, and KK Torus Delilah DiCrescenzo (2005), long-distance runner, inspiration and subject of the Grammy-nominated song Hey There Delilah Michael Quarshie (2005), Finnish American football player who played for the Oakland Raiders and Frankfurt Galaxy Lisa Nemec (2006), Croatian long-distance runner Miloš Tomić (2006), Serbian Olympic rower Erison Hurtault (2007), Dominican sprinter James Leighman Williams (2007), fencer who won silver in the 2008 Summer Olympics Emily Jacobson (2008), fencer İhsan Emre Vural (2008), Turkish rower for Galatasaray S.K. Sherif Farrag (2009), Egyptian-American Olympic fencer Nicholas la Cava (2009), Olympic rower Jeff Spear (2010), Olympic fencer Daria Schneider (2010), fencer Jeff Adams (2011), Houston Texans offensive tackle Nicole Ross (2011), Olympic fencer Isadora Cerullo (2013), Brazilian-American Olympic rugby player Katie Meili (2013), Olympic swimmer, Pan American Games and 2016 Summer Olympics gold medalist Josh Martin (2013), Kansas City Chiefs linebacker John Gregorek Jr. (2014), middle-distance runner David Najem (2014), American soccer player for New Mexico United and the Afghanistan national football team Nadia Eke (2015), Ghanaian triple jumper, African Championships gold medalist in 2016 Kristine Musademba (2015), figure skater Max Schnur (2015), tennis player playing on the ATP Challenger Tour Nzingha Prescod (2015), Olympic fencer Ramit Tandon (2015), professional squash player Jakub Buczek (2016), Canadian Olympic rower Sasha DiGiulian (2016), world champion climber Jacqueline Dubrovich (2016), Olympic fencer Maodo Lô (2016), German basketball player for Brose Bamberg Robb Paller (2016), American-Israeli Olympic baseball player Jeff Coby (2017), American basketball player for Xuventude Baloncesto Cameron Nizialek (2017), football player for Atlanta Falcons Akua Obeng-Akrofi (2018), Ghanaian sprinter Charlotte Buck (2018), Olympic rower Osama Khalifa (2018), #1 ranked college squash player in the U.S. for the 2016–17 season Camille Zimmerman (2018), American basketball player for Norrköping Dolphins Yasmeen Al-Dabbagh (2019), Saudi Arabian sprinter Jessica Antiles (2019), swimmer who won silver and bronze medals in the 2017 Maccabiah Games Dylan Castanheira (2019), soccer player, goalkeeper for Fort Lauderdale CF Sophie Whitehouse (2019), goalkeeper for Republic of Ireland women's national football team Mike Smith (2020), basketball player Anthony Jackie Tang (2020), Hong Kong tennis player John Tanguay (2020), rower who won a silver medal in the 2020 Summer Paralympics Dylan Geick* (2021), wrestler and internet personality Velavan Senthilkumar (2021), British Junior Open Squash champion and Asian Junior Squash champion Nastasya Generalova (2023), gymnast and model Olivia Giaccio (2024), Olympic freestyle skier Evita Griskenas (2024), rhythmic gymnast Camden Pulkinen (2024), figure skater Abbey Hsu (2024), basketball player
Sources: en.wikipedia.org
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.
It normally reports the share of the chromatographic signal that belongs to the main peak, not a measure of activity. A high figure means few related substances were detected under the stated method and wavelength. Different laboratories and methods can return different values for the same material.
Retention time alone is weak evidence, because unrelated peptides can elute at similar positions. Amino acid analysis or peptide mapping gives stronger sequence information when a mass spectrometer is unavailable. Most laboratories still treat mass confirmation as the standard step for verifying the correct compound.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.